INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against The Medicines Company

LOS ANGELES--(BUSINESS WIRE)--

Glancy Binkow & Goldberg LLP reminds investors of The Medicines Company (NASDAQ: MDCO) that all purchasers of The Medicines Company securities between February 20, 2013 and February 12, 2014, inclusive (the “Class Period”), have until April 22, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The Company's products include anticoagulants and treatments for blood pressure control and other cardiovascular indications. The complaint, filed in the United States District Court for the District of New Jersey, alleges violations of federal securities laws and that:

• The Medicines Company issued materially misleading statements concerning the efficacy of its drug candidate Cangrelor, for preventing blood clots during angioplasty and stenting procedures, when compared to clopidogrel – a competing, FDA-approved drug.
• The Company failed to disclose that the CHAMPION clinical trials of Cangrelor were unethically and inappropriately administered.

On February 13, 2014, the price of The Medicines Company shares dropped more than 11% after the Company announced that the Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted against approval of Cangrelor for patients undergoing certain cardiac procedures.

If you are a member of the Class described above, you may move the Court no later than April 22, 2014, to serve as lead plaintiff; however, you must meet certain legal requirements. To be a member of the Class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.